Myriad Genetics (MYGN) Other Operating Expenses (2009 - 2026)

Myriad Genetics has disclosed Other Operating Expenses across 18 years of filings, most recently posting $79.0 million for Q1 2026.

• In Q1 2026, Other Operating Expenses rose 14.16% year-over-year to $79.0 million; the TTM figure through Mar 2026 stood at $610.0 million (up 90.98% YoY), while the FY2025 annual figure was $600.2 million, up 87.8% from the prior year.
• Other Operating Expenses climbed to $79.0 million in Q1 2026, from $71.4 million in the prior quarter.
• Over the last five years, Other Operating Expenses for MYGN reached as high as $388.6 million in Q2 2025 and fell as low as $49.7 million in Q2 2022.
• The 5-year median for Other Operating Expenses is $72.1 million (2024), against an average of $99.1 million.
• Annual changes were most pronounced in 2024 — Other Operating Expenses tumbled 37.62% — and 2025, when it surged 360.43%.
• A 5-year view of Other Operating Expenses shows it stood at $124.9 million in 2022, then declined by 7.45% to $115.6 million in 2023, then fell by 18.94% to $93.7 million in 2024, then retreated by 23.8% to $71.4 million in 2025, then gained by 10.64% to $79.0 million in 2026.
• According to Business Quant data, Other Operating Expenses over the past three periods registered $79.0 million, $71.4 million, and $71.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.